Summary of EUCAST Steering Committee Meeting
Paris, France, 19-20 November 2007

Attending
Dr Derek F.J. Brown DB Scientific Secretary United Kingdom
Dr Rafael Cantón RC Clinical Data Co-ordinator Spain
Dr Fred Goldstein FG SFM France
Prof Gunnar Kahlmeter GK Chairperson Sweden
Prof Alasdair P. MacGowan AM BSAC United Kingdom
Dr Johan W. Mouton JM CRG The Netherlands
Prof Inga Odenholt IO SRGA Sweden
Prof Arne Rodloff AR DIN Germany
Prof Claude-James Soussy CS SFM France
Dr Martin Steinbakk MS NWGA Norway
Apologies
Prof Waleria Hryniewicz WH EUCAST Poland
Prof Pietro Varaldo PV EUCAST Italy
Representing EMEA
Dr Falk Ehman FE EMEA
Dr Eric Pelfrene EP EMEA

1 Chairman’s welcome FG is retiring from the Steering Committee and his major contribution to the work of the committee was acknowledged.
2 Minutes of meeting of 6-7 September 2007 The minutes were accepted as a correct record.
3 Matters arising from minutes of 6-7 September 2007
Minocycline MIC data for H. influenzae are being sought.
National Committee representatives for 2008-11 on the Steering Committee have been confirmed.
The role of EUCAST “post harmonization” is being defined.
Clinical data on fosfomycin are being sought.
Tetracycline breakpoints have been put in a separate table.
4 New drugs Agents which may be presented to EUCAST in the near future were reviewed.
5 New carbapenem Tentative EUCAST breakpoints were discussed.
6 A tetracycline Tentative EUCAST breakpoints for proposed extended indications were discussed.
7 New cephalosporin Tentative EUCAST breakpoints were discussed.
8 Technical notes and rationale documents Rationale documents for quinolones and glycopeptides are on the EUCAST website. The status of others was reviewed.
9 Expert rules subcommittee The comments from the open consultation are being reviewed.
10 Antifungal susceptibility testing subcommittee The fluconazole breakpoints and rationale document are on the EUCAST website and the technical note is in CMI. The yeast MIC method is in CMI. The proposed MIC method for moulds is on the EUCAST website as a discussion document until the end of January 2008.
11 Anaerobe subcommittee Breakpoints have been proposed for all relevant agents.
12 Mycobacterial subcommittee The need for a subcommittee is being discussed.
<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>13</td>
<td><strong>Publications on EUCAST website</strong> Agreed that in most cases EUCAST methodological documents would be published on the website only. A format for citation of documents was agreed.</td>
</tr>
<tr>
<td>14</td>
<td><strong>ECDC</strong> No new information.</td>
</tr>
<tr>
<td>15</td>
<td><strong>EMEA</strong> For information regarding new agents see individual sections.</td>
</tr>
<tr>
<td>16</td>
<td><strong>CLSI</strong> No new information</td>
</tr>
<tr>
<td>17</td>
<td><strong>ECCMID</strong> Workshop on exert rules and symposium on EUCAST breakpoints have been organised.</td>
</tr>
<tr>
<td>18</td>
<td><strong>Macrolide breakpoints</strong> Modifications to proposed breakpoints were agreed and the table finalised.</td>
</tr>
<tr>
<td>19</td>
<td><strong>Miscellaneous agents</strong> Draft breakpoints were reviewed and the updated table will be distributed for final check before release.</td>
</tr>
<tr>
<td>20</td>
<td><strong>Breakpoints for penicillins</strong> Draft breakpoints were discussed in the light of comments from national committees. A revised breakpoint table will be distributed.</td>
</tr>
<tr>
<td>21</td>
<td><strong>New glycopeptide</strong> The agent was presented to the Steering Committee by the company, followed by comments, questions and responses from the Steering Committee.</td>
</tr>
<tr>
<td>22</td>
<td><strong>New glycopeptide</strong> There was further discussion within the Steering Committee (with EMEA).</td>
</tr>
<tr>
<td>23</td>
<td><strong>Oral cephalosporins</strong> Data on current breakpoints and dosages are being collected.</td>
</tr>
<tr>
<td>24</td>
<td><strong>Breakpoints for ESBL screening</strong> It was suggested that epidemiological cut-offs might be used with MIC methods as a more sensitive screen for ESBLs than clinical breakpoints.</td>
</tr>
<tr>
<td>25</td>
<td><strong>EUCAST disc diffusion method</strong> A EUCAST method based on Kirby-Bauer methodology would be easier to adopt in many countries. Agreed to distribute a questionnaire asking what would convince users of disc methods that they should switch to EUCAST breakpoints.</td>
</tr>
<tr>
<td>26</td>
<td><strong>Any other business</strong> None.</td>
</tr>
<tr>
<td>27</td>
<td><strong>Next meetings</strong></td>
</tr>
<tr>
<td></td>
<td>24-25 November 2008. To be decided.</td>
</tr>
</tbody>
</table>

Ratified summary of minutes of meeting 19-20 November 2007. Prepared by DB, GK and RC